key: cord-0764826-ana4h2df
authors: Sodeifian, Fatemeh; Nikfarjam, Mahsa; Kian, Naghmeh; Mohamed, Kawthar; Rezaei, Nima
title: The role of type I interferon in the treatment of COVID‐19
date: 2021-09-17
journal: J Med Virol
DOI: 10.1002/jmv.27317
sha: befb1b25266e92fe0c5e19004140f361c82f65b2
doc_id: 764826
cord_uid: ana4h2df

Although significant research has been done to find effective drugs against coronavirus disease 2019 (COVID‐19) caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), no definite effective drug exists. Thus, research has now shifted towards immunomodulatory agents other than antivirals. In this review, we aim to describe the latest findings on the role of type I interferon (IFN)‐mediated innate antiviral response against SARS‐CoV‐2 and discuss the use of IFNs as a medication for COVID‐19. A growing body of evidence has indicated a promoting active but delayed IFNs response to SARS‐CoV‐2 and Middle East respiratory syndrome coronavirus in infected bronchial epithelial cells. Studies have demonstrated that IFNs' administration before the viral peak and the inflammatory phase of disease could offer a highly protective effect. However, IFNs' treatment during the inflammatory and severe stages of the disease causes immunopathology and long‐lasting harm for patients. Therefore, it is critical to note the best time window for IFNs' administration. Further investigation of the clinical effectiveness of interferon for patients with mild to severe COVID‐19 and its optimal timing and route of administration can be beneficial in finding a safe and effective antiviral therapy for the COVID‐19 disease.

enzyme 2 (ACE2), for cellular entry. 7 Two-thirds of the SARS-CoV-2 genome consists of Open Reading Frame (ORF) 1a and 1b, which encodes replicase polyproteins pp1a and pp1ab, nsp3-PLpro, and nsp5-Mpro of SARS-CoV-2 cleave these polyproteins into nonstructural proteins (nsps), nsp1-11, and nsp1-16, respectively. The remaining genome encodes structural proteins including spike (S), envelope (E), membrane (M), and nucleoprotein (N) as well as accessory proteins (ORF-3a, −3b, −6, −7a, −7b, −8, −9a, −9b, and 10). 8, 9 SARS-CoV-2 uses a similar mechanism to those employed by prior SARS-CoV-1 infection for cell entry. 10, 11 3 | THE LIFE CYCLE OF SARS-CoV-2 SARS-CoV-2 enters host cells via interlocking its spike protein to the host's ACE2 receptor. To complete cell entry, the S protein priming, also known as the proteolytic separation of S1 and S2 proteins of SARS-CoV-2, is needed during the membrane fusion reactions. This phenomenon is facilitated by the host's expression of transmembrane protease serine 2. 7, 12, 13 Several publications have demonstrated that IFN-stimulated genes (ISGs) induce a high expression of ACE2 in host cells and thus enhance virus entry and infection; an article, however, discovered that following SARS-CoV-2 infection, IFNs trigger a truncated version of ACE2 called dACE2, not ACE2 thus, it would not promote the viral entry. 14 The life cycle of SARS-CoV-2 includes the following five steps: (1) its attachment binding the cellular receptor, (2) its penetration and entrance into host cells through endocytosis or penetration, (3) expressing its RNA polymerases in the host cell cytoplasm and starting replication and biosynthesis of other viral contents, (4) mature new viral products are packed, and (5) released from the host cell. 15, 16 Several mechanisms have been proposed to cause cell damage following SARS-CoV-2 entry to host cells, including direct viral cell damage; dysregulating the renin-angiotensin-aldosterone system (RAAS, a type of hormonal system which controls blood pressure, the balance of fluid and electrolyte, vascular permeability, as well as tissue growth), dysregulating the immune system, endothelial cell injury, and thromboinflammation. 12 ACE2 is an essential regulator of the RAAS system; ACE2 converts angiotensin I to inactive angiotensin 1-9 and subsequently converts angiotensin II into angiotensin 1-7. 17, 18 4 | CLINICAL AND IMMUNOLOGICAL CHARACTERISTICS OF COVID-19 PATIENTS COVID-19 disease is classified into three stages: Stage 1 is considered as early infection with the highest degree of host viral response as well as mild symptoms including fever and dry cough, Stage 2 is considered as pulmonary phase, and at last Stage 3 is considered as a hyperinflammation phase, which shows the greatest disease severity as well as presentations of acute respiratory distress syndrome (ARDS). 19 Approximately 20% of patients with COVID-19 manifest severe infection and progress to Stage 3 of the disease, while nearly 80% of patients exhibit mild symptoms of infection and managed to clear viral particles. 20 COVID-19 has a wide range of clinical respiratory symptoms (mild fever, dry cough, sore throat, malaise, headache, and muscle pain) and digestive symptoms (nausea, vomiting, abdominal pain, and diarrhea), as well as hepatic, renal, and neurologic diseases. 9 Pathological damage of the pulmonary system includes pulmonary edema, diffuse alveolar damage associated with the hyaline membrane, fibrosis, and multinucleated giant cells. 20 SARS-CoV-2 infection induces an enhanced innate immune response; following virus entry, necrosis, or pyroptosis of host cells leading to the production of inflammatory cytokines and chemokines, aka the cytokine storm (CS). Thereupon the migration of monocytes/ macrophages and neutrophils to the site of infection resulting in an uncontrolled immune response and severe tissue damage, which consequently contributes to morbidity and mortality. 21, 22 Supportably, according to evidence, the severity of the COVID-19 infection is correlated with the level of inflammatory cytokines. Increased expression of pro-inflammatory cytokines and dysregulated immune response seems to be the leading cause of pathological events and could result in ARDS and organ failure. 23 In patients with the COVID- 19 infection, plasma levels of cytokines and inflammatory factors including interleukin (IL)-1β, IL-7, IL-8, IL-10, IFN-γ, monocyte chemoattractant peptide-1, macrophage inflammatory protein (MIP)-1A, MIP-1B, granulocyte colony-stimulating factor, and tumor necrosis factor-alpha (TNF-α) increase. 24 The disease severity is directly proportional to elevated immune cells, IL-6, TNF-α, the chemokine (C-C motif) ligand 7, and the chemokine (C-X-C motif) ligand 10 (CXCL10). 25 In addition to cytokines and other inflammatory factors, SARS-CoV-2 dysregulates the proper function of immune cells via reducing the total count of B lymphocytes, CD4 + and CD8 + T lymphocytes, and NK cells. Moreover, SARS-CoV-2 simultaneously upregulate expression of NKG2A receptor (a family of C-type lectin receptors on the surface of NK cells), leading to the exhaustion of NK and CD8 + T cells. 26, 27 In contrast to reduced lymphocytes, the levels of neutrophils, leukocytes, and neutrophil-lymphocyte-ratio are increased in severe COVID-19 patients. 23 In conclusion, several organs of the COVID-19 patients undergo prominent immune response dysregulation, hardening the treatment process. 28 Therefore, this review firstly focuses on the role of an innate immune response, especially interferons, in COVID-19 infection, then describes the interaction between SARS-CoV-2 and IFNs based on related clinical studies to pave the way towards finding an effective immunomodulatory agent against the COVID-19 infection.

Innate immune response serves as the first defensive line against pathogens and plays a vital role in antiviral immunity. The first step of innate immunity is initiated by engaging pattern recognition receptors (PRRs). 29 The viral-derived pattern-associated molecular patterns (PAMPs) such as viral single-stranded RNA (ssRNA) and double-stranded RNA (dsRNA) are sensed through the cytosolic retinoic acid-inducible gene-1-like receptor (RIG-1 like receptors, RLRs) and melanoma differentiation-associated protein (MDA5). 30 Moreover , PAMPs are sensed through the endosomal Toll-like receptor   (TLR)3, 7, 8, and 9, anchored on the endosomal membrane TLR-4 deficiency predisposes mice models to SARS-CoV-2 infection.

Adaptor protein molecules such as MyD88 (for TLR4, TLR7, and TLR8) and TRIF (for TLR3 and TLR4) contribute to the protective effect of innate immunity. 31 MyD88 and TRIF are two adaptor protein-dependent signaling pathways known to stimulate inflammatory cytokines and chemokines released after activating specific TLRs, leading to upregulation of immune cell expression. In MyD88-deficient mice, the production of inflammatory cytokines is suppressed, leading to uncontrolled viral replication, severe lung pathology, and more weight loss than wild-type mice during SARS-CoV-1 infection. 31, 32 Similarly, TRIF knockout mice showed decreased inflammatory cytokines in the first two days after coronavirus infection, followed by increased production of IFN-β and inflammatory cytokines on the fourth day of infection. 33 Following activation of MyD88 and TRIF, NF-κB (an essential modulator known as IKKγ) forms a complex with IKKα and IKKβ and phosphorylates NF-κB. On the other hand, activated MDA5 and RIG-1 collaborate with mitochondrial antiviral signaling protein (MAVS). Following the interaction of MDA5 and RIG-1 with MAVS, IKK-related kinase, including TBK1/IKKi is activated, activating IFN regulatory factor (IRF) 3 and 7. 34 Induction of IRF3 and seven increase expression of T1IFN, while nuclear factor-κB (NF-κb) activation triggers the increased production of pro-inflammatory cytokines, including IL-1, IL-6, and TNF-α 34 (Figure 1) SARS-CoV-2 implements different strategies to block PRRs signaling pathways and escape from the innate immune response. It can lead to the degradation of RLRs (RIG-1 and MDA5), essential for recognizing virus dsRNA. 35 It has been shown that hereditary mutations of TLR3-and IRF7-dependent type I IFN signaling cause lethal pneumonia in patients with no underlying diseases. 34 These antiviral agents can promote an adaptive immune response, and interferons can potentially limit the COVID-19 infection.

In addition, SARS-CoV-2 impairs the proper function of the dendritic cells (DCs), which play an essential role in controlling viral "particles" spread as they act as antigen-presenting cells and deliver viral antigens to naïve T cells. DCs present viral antigens through Class II and Class I major histocompatibility complex (MHC) molecules for CD 4+ and CD 8+ T lymphocytes, respectively. 36 SARS-CoV-2 inhibits the expression of costimulatory molecules (CD80/86) on the host cell's surface and interferes with the antigen presentation process response. Moreover, it downregulates the human leukocyte antigen Class II (HLA-II) expression on immature DC cells' surface. As a consequence of this phenomenon, the production of antibodies will be decelerated, accelerating the viral replication. 37 SARS-CoV-2 interacts with DCs function and causes impaired DCs maturation, suppressed T-cell mediated humoral immunity and T cell maturation, and decreased CD4+ and CD8+ levels in the peripheral blood of the COVID-19 patients. 38 DC cells include subpopulations of myeloid DCs, plasmacytoid DCs (pDC), and monocyte-derived DCs. 39 DCs, especially pDCs, produce high amounts of IFNs. A study conducted on pDCs isolated from the peripheral blood of mice models of coronavirus infection demonstrated that these subpopulations of DCs are probably the major source of IFNs expression in response to coronavirus infection. 40 This result suggests that IFNs production by pDCs is critical for the Control and reduction of the replication and spreading of the highly pathogenic coronavirus infection. A recent publication showed that circulating pDCs decreased in the peripheral blood of SARS-CoV-2 infected patients compared to the controls, which can be due to the recruitment of these cells to the infection site. 41 

The IFN-I signaling pathway is initiated through binding to a unique heterodimeric receptor, interferon-alpha receptor (IFNAR). This receptor is expressed in most tissues and compromises two subunits: IFNAR1 and IFNAR2. 42 Following IFNs binding to their receptors, several signaling cascades will occur, ending in transcriptional regulation of ISG. IFNAR1 activates tyrosine kinase 2 (TYK2) in the first signaling pathway, while IFNAR2 seems to be associated with the Janus activated kinase (JAK1). TYK2 and JAK1 phosphorylate conserved tyrosine residues in the cytoplasmic tails of the IFNAR. These phosphorylated residues recruit src-homology 2-containing signaling molecules, including STAT1 and STAT2. STAT1 and STA2 are then phosphorylated and dimerized. In the next step, the IFN-regulatory factor 9 (IRF9) binds to them and forms the ISG factor 3 (ISGF3) transcription factor complex, which then moves to the nucleus and binds to the IFN-stimulated response elements (ISRE) 43 (Figure 2 ).

Several proteins of SARS-CoV-2 interfere with the signaling pathways of NF-κB and IRF3/7. ORF6, ORF8, and nucleocapsid proteins of SARS-CoV-2 strongly repress type I interferon (IFN-β) signaling pathway and NF-κB activation. 44 Further studies demonstrated that Orf9b of SARS-CoV-2 inhibits type I interferon responses. 45 Moreover, ORF3b proteins of SARS-CoV-2 have a similar effect on the IFN signaling pathway. 46 Similarly, ORF9b of SARS-CoV-2 antagonizes IFN expression through interaction with multiple components of RIG-I/MDA-5-MAVS and TLR3. 47 As another viral strategy, the S protein of SARS-CoV-2 induces the expression of SOCS3/1 (suppressor of cytokine signaling) in infected cells. The induction of SOCS1/3 represses IFNs production and increase SARS-CoV-2 replication in infected cells.

Antiviral actions of IFNs can be classified into six classes ( Figure 3 ).

First, protein kinase-R is activated upon viral infection through an autophosphorylation process induced by IFNs signaling. 48 Moreover, dsRNA mediates the activation of PKR. PKR activation catalyzes the phosphorylation of the α subunit of initiation factor 2 (eIF2α, also known as an inhibitor of transcription factor IkB), which decreases mRNA translation and subsequent inhibition of viral protein synthesis. 49 Activated PKR induces the activation of transcription factor NF-κB through the phosphorylation of its inhibitory subunit, IkB.

Activated NF-κB promotes the expression of inflammatory cytokines SODEIFIAN ET AL. and prohibits the virus from spreading through the host cells. 50 It is not well understood whether the novel coronavirus modulates the PKR pathway, but accessory protein 4a (p4a) of Middle East respiratory syndrome coronavirus (MERS-CoV) blocks the PKR pathway and increases viral replication. 51 Further studies are needed to discover the interplay between SARS-CoV-2 and PKR pathways.

Second, IFNs induce the activation of 2ʹ−5ʹ oligoadenylate synthesis (OAS), which phosphorylates 2ʹ−5ʹ oligoadenylate (2,5A).

Subsequently, 2,5A activates latent RNase that results in viral RNA degradation. 52 Third, IFNs activate nitric oxide synthase (NOS); NOS catalyzes the oxidation of arginine to produce citrulline and nitric oxide (NO). The latter exhibits cytotoxic effects that result in the death of the infected cells.

Fourth, adenosine deaminase acting on RNA (ADAR) is triggered by IFNs and catalyzes the deamination of adenosine to inosine (A-to-I editing) that leads to RNA editing. 49 F I G U R E 1 Innate immune response In the first step, infectious viral particles (PAMPs) were sensed through PRRs. SARS-CoV-2 is detected through endosomal PRRs including TLR 3, 7, 8, and 9 and/or through cytoplasmic PRRs such as MDA5 and RIG-1. Moreover, the virus can be sensed through TLR4, which is localized in the cell membrane. Following TLRs activation, NF-'kB's transcription factor induces inflammatory cytokines, whereas activated MDA5 and RIG-1 recruit IRF3 and IRF7 for interferon production. When interferon binds its receptor, IFRAR1/2, an IFN-induced signaling pathway is initiated, resulting in the recruitment of JAK-1 and TYK. JAK-1 and TYK activation trigger the phosphorylation of the signal transducer and activator of transcription (STAT)1 and 2, respectively. Subsequently, an IFN-stimulated gene factor 3 (ISGF3) complex is formed, containing STAT1, STAT2, and IRF-9. This complex translocated to the nucleus and increases the expression of IFN-stimulated genes (ISGs). ISGs translation and posttranslational modification trigger antiviral action interferons, including Inhibition of mRNA inhibition, RNA degradation, RNA editing, and the initiation of T cell response, and NO synthesis. IFN, interferon; IRF, IFN regulatory factor; MDA, melanoma differentiation-associated protein; mRNA, messenger RNA; PRRs, pattern recognition receptors; RIG, retinoic acid-inducible gene-1-like receptor; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; TLR, Toll-like receptor Fifth, the expression of Mx genes is mediated by type I and III interferons; Mx proteins inhibit the early stage of the replication cycle of a wide range of viruses, especially negative-stranded RNA viruses, through their GTPase activity. 53, 54 Lastly, it has been shown that following viral infection, interferons can increase the level of MHC class I and II to better inhibit viral replication. IFN-treated human cells have elevated MHC antigen levels. Viral infection activates MHC Class I-restricted CD8+ T cells and MHC class II-restricted CD4+ T cells, presenting antigen peptides to cytotoxic T cells. 55, 56 In the early stage of the disease, IFNs exert a highly potential antiviral activity by stimulating antigen-presenting cells (APC) such as F I G U R E 2 Interferon signaling pathway. IFN, interferon; IRF, IFN regulatory factor; IFNAR, interferon-alpha receptor; ISRE, IFN-stimulated response elements; JAK, Janus activated kinase; TYK, tyrosine kinase F I G U R E 3 Antiviral actions of interferons. ADAR, adenosine deaminase acting on RNA; dsRNA, double-stranded RNA; IFNs. interferons; mRNA, messenger RNA; OAS, 2ʹ−5ʹ oligoadenylate synthesis SODEIFIAN ET AL. | 67 natural killer cells and dendritic cells. 57 Similarly, IFNs show an impressive capacity for enhancing and regulating key immune cells, such as localization and differentiation of virus-specific T cells, the turnover of memory T cells, and the recruitment of T and B lymphocytes to the infection site. 57 IFNs expression upregulates the level of transmembrane protein (IFITM3), which is involved in the fusion of the pathogenic virus and endocytic vesicles and combines it with the lysosomes. In this way, the host cell prevents viral "particles" release into the cytoplasm and controls viral spread. 58 It has been suggested that type 1 interferon impairment in severe and critical cases of COVID-19 is associated with deteriorated inflammatory response and higher viral load in the blood. NF-κB is considered as the main driving factor in exacerbating the disease, indicating the vitality of the deficiency or the impairment of the IFN-I signaling pathway in the COVID-19 infection. 59 Briefly, IFN is suggested to be the first defensive line against viral infection and its downregulation or delayed action, as discussed later, can lead to a more severe form of the disease and viral spread throughout the host body. Clinical studies have reported that SARS-CoV-1 induces impaired IFN expression following infection. 61, 62 Other studies also suggest that IFNs expression can be delayed during SARS-CoV-1 pathogenesis. 63 A growing body of evidence indicated that human bronchial epithelial cells, rather than complete absence, promote active but delayed IFNs response to SARS-CoV-2 and MERS-CoV infection. 63, 64 As COVID-19 triggers a robust production of inflammatory cytokines and induces impaired/delayed IFNs expression, it is assumed that infected patients show the accumulation of pathogenic monocyte/macrophage (IMMs), increased lung pathology, and dysregulated viral-specific T cell response. 65 Depending on the onset of IFNs production in SARS-CoV-2 infection, disease severity can be categorized into three types: (1) early response of type 1 IFNs leads to decreased viral titers, regulated inflammatory response, and mild-clinical features; (2) delayed response causes dysregulated IMM response, lung damage, and severe pneumonia; (3) and lastly, the absence of type 1 IFNs signaling pathways results in invasive ventilation (delivering positive pressure through an endotracheal tube), poorer outcomes, higher viral load, and longer intensive care unit admission. 66 Inconsistently, the increased expression of IFNs contributes to disease severity and viremia in COVID-19 patients. 62 The peripheral blood mononuclear cells (PBMC) of the COVID-19 patients demonstrated that the viral load is associated with enhanced type 1 IFNs and disease severity. 41 Furthermore, increased IFNs at the later stages of the severe COVID-19 cases worsen the pathophysiology and is accompanied by pyroptosis (a highly inflammatory programmed cell death that occurs in infected cells). 67, 68 Similarly, in a cohort of COVID-19 patients, high viremia, as well as disease severity, was associated with IFN-α and ISGs levels. 41 Moreover, IFN signaling is pivotal for recruiting inflammatory cells to the infection site, but it cannot clear viral particles and control viral replication. 69 As aforementioned, it can be due to late IFN expression or since SARS-CoV-2 dampens IFN responses and ISG induction through nonstructural protein (nsp) 1, nsp 6, nsp 13, ORF3a, M, ORF7a, ORF7b, and ORF6. 70 To explain these paradoxical effects of IFNs administration and achieve a beneficial effect and maximal protection of IFNs in the treatment of SARS-CoV-2, it is critical to notice the best time window for IFNs administration. IFNs administration before the viral peak and inflammatory phase of disease could offer a highly protective effect, while IFN treatment during the inflammatory and severe stages of the disease would rather cause immunopathology and long-lasting harm. 62, 71 Early exogenous administration of IFN-β showed a full protective effect against virus replication and expression of inflammatory cytokines in mice models of MERS-CoV infection. In contrast, delayed Treatment with IFN-β resulted in the high production of type 1 interferon, inflammatory cytokines, and ISGs. 72 The same concepts of the critical role of timing of IFNs administration were also concluded in the clinical trials. 73 It is worth mentioning that COVID-19 treatment guidelines recommend against the therapeutic effectiveness of IFNs for severe or critical SARS-CoV-2-infected patients. In addition to the influential role of IFNs therapy in infected patients, it has been demonstrated that IFNs treatment may offer a defensive effect against viral invasion in asymptomatic people who had been exposed to infected patients.

Hence, this result shows that pretreatment with IFNs can stop SARS-CoV-2 infection before its occurrence. 71 Besides the essential role of the early administration of IFNs for COVID-19 patients, studies also showed homozygosity for the C allele of rs12252 in the interferon-induced transmembrane protein 3 (IFITM3) gene, supporting the severity of disease in an agedependent manner. This explains why the minority of infected patients develop progressive disease and show severe and lethal infection, while others manifest mild or moderate symptoms. 74 However, a German cohort reported that polymorphism in the IFITM3 gene, including rs12252 and rs34481144 variants, do not influence the disease severity or risk of infection. 75 A worldwide epidemiological study demonstrated that a minor allele of rs12252 polymorphism has a beneficial effect against SARS-CoV-2 infection, but a minor allele for rs34481144 can increase the SARS-CoV-2 infection and mortality. 76 Further studies are needed to determine the exact association between the population's genetic variants and the risk of SARS-CoV-2 severity. In addition to disease severity and the COVID-19 infection risk, studies also demonstrated a strong correlation between the rate of case fatality in COVID-19 infection and the allele frequency in the IFITM3 gene. As the first report, Kim et al. 77 revealed the positive correlation between fatality rate and rs6598045 single-nucleotide polymorphism in the IFITM3 gene. 77 Thus, appropriate and timely IFN treatment of this group of patients may protect them from lethal and pathogenic infection. As mentioned before, SARS-CoV-2 interferes with the interferon I-mediated immune response. 78 In vitro implication of type I IFN inhibits the replication of SARS-CoV-2, SARS-CoV-1, and MERS-CoV in cultural cell lines and animal models of viral infection. 79 An in vitro experiment comparing IFN-I sensitivity between SARS-CoV-1 and the novel SARS-CoV-2, using Vero E6 and calu3 cells, has firmly proposed that SARS-CoV-2 is significantly more sensitive to IFN-I treatment either pre-or postinfection. The study has attributed higher sensitivity of SARS-CoV-2 to the lack of an equivalent ORF3b and some genetic differences against ORF6 in SARS-CoV-2, which are both known as IFN antagonizing factors. Moreover, pretreatment of

results, with SARS-CoV-2 infected cells being unable to stimulate IFN-I release before treatment and unsuccessful to counteract the phosphorylation of STAT-I when pretreated with IFN-I. 80 The combination of IFN-α and IFN-β exhibits dramatic antiviral effects in Vero cells infected with SARS-CoV-2 which were lacking IFN-α and IFN-β genes; the study predicted that IFN-β administration could be more effective on IFN-competent cells, as IFN-β upregulates the expression of other IFN-I subtypes and reinforces the IFN dependent immune response. 81 IFN-β1b has also shown a striking antiviral activity in IFN-deficient cells. 82 In line with this finding, one publication has proposed that treating Vero cells with recombinant IFN-I is associated with a 30-40 folds reduction in viral titers. 83 Interestingly, one manuscript comparing transcriptional status in juvenile and old rhesus macaques following SARS-CoV-2 infection found that IFN-I expression was more upregulated in the lungs of juvenile macaques than the old ones might justify the age risk factor in COVID-19 infection. 84 This publication suggested that the induction of type I interferon signaling pathway in juvenile macaques infers its protective role rather than a deteriorative effect on disease progression. 85 Investigating bats' cell lines, some protective signaling pathways were found that might explain the viral tolerance of bats' immune system against SARS-CoV-2, with one of them being perpetual IFN-α expression as was seen in the cells of Pteropus Alecto bats. 86 Previous studies have shown that PEGylated IFN-α protected type I pneumocytes reduced the pulmonary damage in SARS infected macaques. 87 It has been demonstrated that IFN-α shows a better in vitro inhibitory effect against SARS-CoV-1 virus growth than ribavirin. 88 Comparatively, IFN-β 1a showed a potential inhibitory effect against SARS virus replication in vitro. 89 Moreover, IFN-α/β, combined with IFN-γ, inhibits viral RNA replication and DNA replication. 90 Some in vitro studies suggested that IFN-I produces a potential antiviral activity against SARS-CoV-1 rather than IFN-γ, 80, 91, 92 but other studies have demonstrated that combined administration of IFN-I and IFN-γ synergistically inhibits viral replication in vitro. 93 In addition to IFN therapy alone, studies showed that IFN-β, combined with antiviral drugs, Ribavirin, would produce antiviral activity synergistically in Vero cells. 94 A similar result was achieved through the combination of IFN-α2b with ribavirin in infected cultural cells of SARS-CoV-1. 95 The matter of timing in IFNs administration is a highly critical issue in animal models. IFN-I administration before the viral peak results in complete protection and regulates the lethal replication of the virus in ifnar1 −/− BALB/c mice. However, after the viral peak, the late delivery of IFNs failed to establish a protective effect and caused severe infection of SARS-CoV-1. 65 In another manuscript, early administration of IFN-β before the viral peak led to protective effect, while its late delivery caused inflammation and severe pneumonia. 72 

Since the outbreak of COVID-19, massive efforts have been devoted to finding the optimal therapeutic and preventive approach to break the contagion chain. Numerous studies, some of which we reviewed here, have investigated interferon therapy to assess its effectiveness In previous studies on mice models, early treatment by IFN rescued SARS-CoV-1, or MERS infected mice, while late treatment was followed by an exacerbated immune response. 97 The results from two in vitro studies have shown that SARS-CoV-2 is much more sensitive to IFN-I administration than other SARS-CoVs; these SODEIFIAN ET AL. | 69 findings suggest that IFN-α or IFN-β administration is associated with a significant reduction in viral loads and that IFN administration can be used as a prophylactic factor or early treatment for this family of viruses. 62 IFN-α is known to reduce viral shedding and inflammatory markers, while IFN-β is associated chiefly with improved viral clearance. 98 In addition to that, it has been firmly suggested that IFN-β is more effective than IFN-α on SARS-CoV-2 99 Clinical Improvement (OSCI) and lower incidence of adverse events. 100 Similarly, one randomized clinical trial has recently shown that using IFNβ−1a nebulizers is associated with clinical improvement in hospitalized COVID-19 patients, based on OSCI; whereas, placebo and treatment groups did not differ in hospital discharge rate by Day

The effect of IFNs on mortality rates differed in several studies. A randomized controlled trial evaluating the efficacy of IFN-β1a in patients with severe COVID-19 showed a significantly lower 28-day mortality rate in the IFN-received group (receiving IFN in addition to hydroxychloroquine, lopinavir/ritonavir, or atazanavir/ritonavir). 102 In contrast, a relatively similar publication using IFN-β1b (combined with the same drugs just mentioned above) showed no significant change in the 28-day mortality outcomes. 103 The efficacy of the intramuscular form of INF-β1b (betaferon) has been evaluated in a retrospective cohort study; it was indicated that this treatment had no significant impact on in-hospital survival. Both study groups in this article received other effective drugs such as hydroxychloroquine, antivirals (liponavir/ritonavir), and/or anti-inflammatory drugs (steroids and/or tocilizumab), making the comparison difficult. 104 A recent randomized clinical trial compared clinical outcomes in two groups of COVID-19 patients with moderate to severe pneumonia, with one of them receiving favipiravir and interferon beta-1b, and the other one receiving hydroxychloroquine; the length of hospital stay, intensive care unit (ICU) admissions, discharge, and mortality rates, oxygen saturation at discharge, and changes in the inflammatory biomarkers at the time of discharge were not significantly different between the two groups. 105 Moreover, a more extensive cohort study on the therapeutic effectiveness of intramuscular administration of IFN-α2b in combination with oral antivirals such as lopinavir/ritonavir plus chloroquine (as recommended in Cuban protocol of COVID-19) suggested that the patients receiving Heberon Alpha R (IFN-α2b, liquid formulation) showed improved recovery rates as well as lower fatalities. 106 The 103 However, the latter publication showed positive outcomes in severe cases of COVID-19, such as a significant increase in discharge rate at Day 14, a decreased need for ICU admission but not the length of ICU stay, and shortened time to reach clinical response. 103 A recent meta-analysis study has concluded that interferon-1 therapy is associated with a higher discharge and lower deaths than standard care groups. Simultaneously, the need for ICU transforms, mechanical ventilation, or severe or critical disease development did not differ between them. 108 Another meta-analysis study has recently investigated clinical trials on the therapeutic effects of IFN-β; the results support the effectiveness of IFN-β on improving discharge rate, duration of hospital stays, and in some cases, mortality. The study has suggested that administration of IFN-β with other antivirals in the early days of viral shedding improves viral clearance and antiviral response, especially in patients with autoantibodies against IFN-I. 99 in patients with mild to moderate COVID- 19. 110 Conversely, the combination of IFNβ1 with lopinavir/ritonavir was associated with higher survival and discharge rates and improvement in oxygen supply in hospitalized COVID-19 patients. 111 Another retrospective multicenter cohort study also supported improvement in the clinical findings of COVID-19 patients with pneumonia. The results from this publication showed that patients who received Arbidol/IFN-α2b treatment experienced CT improvement sooner than nucleic acid clearance; they also benefited from the treatment in terms of reducing their incidence of lung inflammation without invasive ventilation techniques compared with those who only received IFN-α2b, suggesting a synergistic effect that Arbidol/ IFN-α2b combination can bring about; the RNA clearance and hospital stay days were not changed, though. 112 Additionally, the incidence rates of common and serious adverse events in severe cases of COVID-19 who received IFN-β1b were less than the control group. 103 The same manuscript also demonstrated that the markers of acute inflammation, such as C-reactive protein and IL-6, decreased in the treatment course. 8 The authors found more promising findings in their subsequent publication that included extended analysis on the same study groups; the analysis indicated that interferon treatment reduces CT scores and prevents exacerbation of lung abnormalities by restricting the effect of SARS-CoV-2 infection on reducing CD8+

T cells and increasing IL-6 and TNF-α levels. 116 Interestingly, the findings of a randomized controlled trial comparing the effectiveness of INF-α2b/IFN gamma (HeberFERON) treatment with IFN-α2b alone (Heberon Alpha R) indicated that HeberFERON is a safe treatment and more effective in shortening the time of virus elimination with more than 95% of patients becoming negative for SARS-CoV-2 within 5 days of treatment. 117 Recently, a three-armed randomized controlled trial has compared IFNβ1a and IFNβ1b together and with a control group; time to clinical improvement was similar between IFN groups and slightly lower than the control group; moreover, the number of deaths was also lower in treatment groups while there was no significant difference in the occurrence of adverse events between the three arms. 118 Besides the discussions around the efficacy of IFN therapy, its administration's timing is proposed to be of utmost importance. The results from a randomized controlled trial demonstrated that patients who received a combination of IFN-β1a and lopinavir/ritonavir or atazanavir/ritonavir plus hydroxychloroquine in the early phases of the disease experienced significantly more benefits from the treatment. 102 Additionally, a cohort study also supported an association between early administrations of IFN-α2b with a significant reduction in mortality rate, whereas late administration was correlated with increased deaths and delayed recovery. 119 Generally speaking, the optimal time for IFN administration appears to be the early stages of the disease to maximally achieve its biological activities and prevent the progression to the severe forms of COVID-19. 57 The article has proposed the best therapeutic window for IFN-α or -β administration to be in the first 10 days from COVID-19 diagnosis; if IFN administration is carried out around the viral peak when the virus mediates stimulation of alveolar macrophages and epithelial cells of lungs to secrete significant amounts of inflammatory cytokines (i.e., CS), the likelihood of adverse events occurring in patients will be significantly increased. Another beneficial effect of early administration of IFNs is seen among old patients deficient in proper IFN signaling activity and have a lower innate and adaptive immune response. 57 A recent propensity-score analysis study suggested that administering IFNα−2b beyond 7 days after symptoms onset can turn the antiviral effects into pro-inflammatory ones. 113 The IFN administration route might be another determinant factor in evaluating its efficacy; some studies have suggested IFN aerosols or nebulizers as a possible solution since they can be directly and noninvasively delivered to the lungs and reach a higher local concentration than the intramuscular form. 96 A recent clinical trial was carried out on Chinese medical staff exposed to COVID-19 at low-or high-risk levels, they were both receiving IFN-α nasal drops (2) IFN significantly improved the discharge rate by day 14.

(3) The 28-day mortality was significantly lower in the IFN group.

(4) Patients who received IFN in the early phase of the disease experienced significantly more benefits from the Treatment. (1) Patients in the early IFN-a2b administration group showed a lower mortality rate than those with no IFN-a2b admission.

(2) Patients who received late administration of IFN-a2b experienced increased mortality.

(3) Late IFN-a2b administration was associated with delayed recovery among survivors.

(4) Early IFN-a2b and Umifenovir alone or in combination were associated with reduced mortality and a faster recovery in comparison with Treatment with lopinavir/ ritonavir (LPV/r) alone. and first-level protection, but the high-risk group was also supplied by second-or third-protection level and thymosin-α1; both studied groups benefited from the preventive effects of the interventions for 28 days. 120 Another clinical trial in the UK evaluated the efficacy of nebulized IFN-β1a (SNG001) to treat COVID-19 patients. 'Patients'

follow-up for 28 days revealed that the patients treated by SNG001

showed accelerated recovery and general improvement compared with the placebo group. 100 Nasal administration of IFN-α and IFN-β is proposed to be a functional and relatively safe strategy, especially for prophylactic uses in those at a high exposure to infected patients such as medical staff or house caregivers. 57 The sublingual administration route has recently gained much attention due to its prophylactic effect in healthy individuals and lack of hepatic and neurotoxicity concerns; sublingual IFN-I administration can exert its antiviral effects through a local interaction between the given interferon and the cytokines and specific immune cells such as intraepithelial T cells which are known to mediate IFN function. 57 Chuan et al. 97 conducted a randomized clinical trial to evaluate the effectiveness of the traditional interferon-alpha in comparison with recombinant super-compound interferon (rSIFN-co) (a new genetically engineered interferon but is not commercialized yet). rSIFN-co resulted in significantly shorter clinical improvement compared with interferon-alpha in COVID-19 cases. 117 More potent during preclinical therapy, rSIFN-co has more substantial antiviral effects, and fewer side effects than traditional interferon-alpha. 13 and 18 patients in the rSIFN-co group interferon-alpha group showed adverse events (AEs), respectively. Most of the AEs categorized as grade or two, and no severe AEs were reported. 117 More detailed information on study design, intervention, and outcomes of mentioned clinical studies is displayed in Table 1 .

There is a controversy about the effectiveness of IFN therapy alone or in combination with other antiviral drugs, thus making it more challenging for us to integrate all the results into one unique conclusion. Based on this review, Interferon therapy, in general, effectively improves some clinical aspects of COVID-19 and reduces the mortality rate if utilized properly and in the proper combination.

However, its effect is not definite in all study groups and might depend on the patient's polymorphisms or the disease phase. 62 It has been firmly suggested that IFN administration before the viral peak exerts the maximum protective effect without adverse pathological consequences. 62 Administrating IFNs in the later stages of the infection, on the other hand, exacerbates the disease severity due to excessive inflammation and direct tissue damage. 96 Further investigation on the clinical effectiveness of interferons for patients with mild to severe COVID-19 and its optimal timing and route of administration can help find a safe and functional antiviral therapy for COVID-19 disease.

There is no funding for the current study.

The authors declare that there are no conflict of interests. 

Data sharing not applicable to this article as no datasets were generated or analyzed during the current study.

Nima Rezaei http://orcid.org/0000-0002-3836-1827

Resolution of coronavirus disease 2019 (COVID-19)

Treatment options for COVID-19: the reality and challenges

Dulebohn SC & Napoli RD Features, evaluation, and treatment of coronavirus (COVID-19)

JAK-inhibitor and type I interferon ability to produce favorable clinical outcomes in COVID-19 patients: a systematic review and meta-analysis

Functional exhaustion of Type I and II interferons production in severe COVID-19 patients

Origin and evolution of pathogenic coronaviruses

SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor

A pneumonia outbreak associated with a new coronavirus of probable bat origin

A review on SARS-CoV-2 virology: pathophysiology animal models, and anti-viral interventions

Structural basis of receptor recognition by SARS-CoV-2

SARS-CoV-2: s comprehensive review from pathogenicity of the virus to clinical consequences

Extrapulmonary manifestations of COVID-19

The structural basis of accelerated host cell entry by SARS-CoV-2

Interferons and viruses induce a novel truncated ACE2 isoform and not the full-length SARS-CoV-2 receptor

COVID-19 pathophysiology: a review

SARS-CoV-2: A comprehensive review from pathogenicity of the virus to clinical consequences

Adverse events following cannabis for medical use in Tuscany: an analysis of the Italian Phytovigilance database

Trilogy of ACE2: a peptidase in the renin-angiotensin system, a SARS receptor, and a partner for amino acid transporters

COVID-19 illness in native and immunosuppressed states: a clinical-therapeutic staging proposal

Development of an inactivated vaccine candidate for SARS-CoV-2

The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): the perspectives of clinical immunologists from China

Cytokines and COVID-19: friends or foes? Hum Vaccines Immunother

COVID-19, immune system response, hyperinflammation and repurposing antirheumatic drugs

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

In the eye of the COVID-19 cytokine storm

Functional exhaustion of antiviral lymphocytes in COVID-19 patients

Apoptosis and immunophenotyping of peripheral blood lymphocytes in Iranian COVID-19 patients: Clinical and laboratory characteristics

Computational drug discovery and repurposing for the treatment of COVID-19: a systematic review

Innate immune response to viral infection

Immunology of COVID-19: current state of the science

MyD88 is required for protection from lethal infection with a mouse-adapted SARS-CoV

Toll-like receptor 4 deficiency increases disease and mortality after mouse hepatitis virus type 1 infection of susceptible C3H mice

Toll-like receptor 3 signaling via TRIF contributes to a protective innate immune response to severe acute respiratory syndrome coronavirus infection

Inborn errors of type I IFN immunity in patients with life-threatening COVID-19

Distinct RIG-I and MDA5 signaling by RNA viruses in innate immunity

Cross-priming of CD8+ T cells stimulated by virus-induced type I interferon

Innate immune evasion by SARS-CoV-2. Comparison with SARS-CoV

Acute SARS-CoV-2 infection impairs dendritic cell and T cell responses

Immune response in SARS-CoV-2 infection: the role of interferons type I and type III

Control of coronavirus infection through plasmacytoid dendritic-cell-derived type I interferon

Impaired type I interferon activity and exacerbated inflammatory responses in severe COVID-19 patients

Type I interferon receptors biochemistry and biological functions

Direct effects of type I interferons on cells of the immune system

The ORF6, ORF8 and nucleocapsid proteins of SARS-CoV-2 inhibit type I interferon signaling pathway

SARS-CoV-2 Orf9b suppresses type I interferon responses by targeting TOM70

SARS-CoV-2 ORF3b is a potent interferon antagonist whose activity is increased by a naturally occurring elongation variant

SARS-CoV-2 ORF9b antagonizes type I and III interferons by targeting multiple components of RIG-I/MDA-5-MAVS, TLR3-TRIF, and cGAS-STING signaling pathways

Interferon Action and the Double-Stranded RNA-Dependent Enzymes ADAR1 Adenosine Deaminase and PKR Protein Kinase

Antiviral actions of interferons

The role of nuclear factor κB in the interferon response

Middle East respiratory coronavirus accessory protein 4a inhibits PKR-mediated antiviral stress responses

Interferon-inducible antiviral effectors

Interferon-induced Mx proteins in antiviral host defense

Editor-in-Chief

The MHC class I antigen presentation pathway: strategies for viral immune evasion

Viral inhibition of MHC class II antigen presentation

Are we fully exploiting type I Interferons in today's fight against COVID-19 pandemic?

Interferon-induced transmembrane protein (IFITM3) is upregulated explicitly in SARS-CoV-2 infected lung epithelial cells

Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients

Adaptive immunity to SARS-CoV-2 and COVID-19

The immunobiology of SARS

Type I and Type III interferons-induction, signaling, evasion, and application to combat COVID-19

Dynamic innate immune responses of human bronchial epithelial cells to severe acute respiratory syndrome-associated coronavirus infection

Attenuation and restoration of severe acute respiratory syndrome coronavirus mutant lacking 2′-O-methyltransferase activity

Dysregulated type I interferon and inflammatory monocyte-macrophage responses cause lethal pneumonia in SARS-CoV-infected mice

Type I IFN immunoprofiling in COVID-19 patients

The double edged interferon riddle in COVID-19 pathogenesis

Dysregulated interferon response underlying severe COVID-19

Mouse model of SARS-CoV-2 reveals inflammatory role of type I interferon signaling

SARS-CoV-2 triggers an MDA-5-dependent interferon response which is unable to control replication in lung epithelial cells

Can interferons stop COVID-19 before it takes hold?

IFN-I response timing relative to virus replication determines MERS coronavirus infection outcomes

Retrospective multicenter cohort study shows early interferon therapy is associated with favorable clinical responses in COVID-19 patients

Interferon-induced transmembrane protein 3 genetic variant rs12252-C associated with disease severity in coronavirus disease 2019

The influence of IFITM3 polymorphisms on susceptibility to SARS-CoV-2 infection and severity of COVID-19

Minor allele of interferoninduced transmembrane protein 3 polymorphism (rs12252) is covered against severe acute respiratory syndrome coronavirus 2 infection and mortality: a worldwide epidemiological investigation

Strong correlation between the case fatality rate of COVID-19 and the rs6598045 single nucleotide polymorphism (SNP) of the interferon-induced transmembrane protein 3 (IFITM3) gene at the population-level

Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial

Inhibition of SARS-CoV-2 by type I and type III interferons

Type I interferon susceptibility distinguishes SARS-CoV-2 from SARS-CoV

Antiviral activities of type I interferons to SARS-CoV-2 infection

Interferon-β−1a inhibition of severe acute respiratory syndrome-coronavirus 2 in vitro when administered after virus infection

A review on SARS-CoV-2 virology, pathophysiology, animal models, and antiviral interventions

Animal Models for SARS-CoV-2 research: a comprehensive literature review

IFN signaling and neutrophil degranulation transcriptional signatures are induced during SARS-CoV-2 infection

Animal models of mechanisms of SARS-CoV-2 infection and COVID-19 pathology

Pegylated interferon-α protects type 1 pneumocytes against SARS coronavirus infection in macaques

Severe acute respiratory syndromerelated coronavirus is inhibited by interferon-α

Interferon-β 1a and SARS coronavirus replication

Interferon-beta and interferon-gamma synergistically inhibit the replication of severe acute respiratory syndrome-associated coronavirus (SARS-CoV)

Potent inhibition of SARSassociated coronavirus (SCoV) infection and replication by type I interferons (IFN-α/β) but not by type II interferon

Antiviral activities of type I interferons to SARS-CoV-2 infection

Interferon-beta and interferon-gamma synergistically inhibit the replication of severe acute respiratory syndrome-associated coronavirus (SARS-CoV)

Ribavirin and interferon-β synergistically inhibit SARS-associated coronavirus replication in animal and human cell lines

Inhibition of novel β coronavirus replication by a combination of interferon-α2b and ribavirin

Interplay between SARS-CoV-2 and the type I interferon response

Engineered interferon alpha effectively improves clinical outcomes of COVID-19 patients

A narrative review of pharmacologic treatments for COVID-19: safety considerations and ototoxicity

Interferon-beta offers promising avenues to COVID-19 treatment: a systematic review and meta-analysis of clinical trial studies

Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial

Nebulised interferon beta-1a for patients with COVID-19

A randomized clinical trial of the efficacy and safety of interferon β-1a in treatment of severe COVID-19

Interferon β−1b in treatment of severe COVID-19: a randomized clinical trial

Clinical evaluation of IFN beta1b in COVID-19 pneumonia: a retrospective study

Randomized controlled open label trial on the use of favipiravir combined with inhaled interferon beta-1b in hospitalized patients with moderate to severe COVID-19 pneumonia

Therapeutic effectiveness of Interferon-α2b against COVID-19: the Cuban experience

WHO Solidarity Trial Consortium. Repurposed antiviral drugs for COVID-19; interim WHO Solidarity Trial results

JAK-inhibitor and type I interferon ability to produce favorable clinical outcomes in COVID-19 patients: a systematic review and meta-analysis

Therapeutic effectiveness of interferon alpha 2b treatment for COVID-19 patient recovery. medRxiv

Clinical characteristics of chronic liver disease with coronavirus disease 2019 (COVID-19): a cohort study in Wuhan

Combination therapy of IFNβ1 with lopinavir-ritonavir, increases oxygenation, survival and discharging of sever COVID-19 infected inpatients

Arbidol/IFN-α2b therapy for patients with coronavirus disease 2019: a retrospective multicenter cohort study

Clinical outcomes of different therapeutic options for COVID-19 in two Chinese case cohorts: a propensity-score analysis

Efficacy and safety of pegylated interferon Alfa-2b in moderate COVID-19: a phase II, randomized, controlled, open-label study

Response to pegylated interferon in a COVID-19-positive elderly woman with primary myelofibrosis treated with ruxolitinib

Interferon-α2b treatment for COVID-19 is associated with improvements in lung abnormalities

Effect and safety of combination of interferon alpha-2b and gamma or interferon alpha-2b for negativization of SARS-CoV-2 viral RNA. Preliminary results of a randomized controlled clinical trial

Role of interferon therapy in severe COVID-19: The COVIFERON randomized controlled trial

Retrospective multicenter cohort study shows early interferon therapy is associated with favorable clinical responses in COVID-19 patients

An experimental trial of recombinant human interferon alpha nasal drops to prevent coronavirus disease 2019 in medical staff in an epidemic area

No statistically apparent difference in antiviral effectiveness observed among ribavirin plus interferonalpha, lopinavir/ritonavir plus interferon-alpha, and ribavirin plus lopinavir/ritonavir plus interferon-alpha in patients with mild to moderate coronavirus disease 2019: results of a randomized, openlabeled prospective study

The role of type I interferon in the treatment of COVID-19